Symphogen buys tumor blocking technology

The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.

The Danish biopharmaceuticals company Symphogen has acquired the technology and programs of the american company Receptor Biologix. Symphogen is a leader in developing recombinant polyclonal antibodies, a new class of biopharmaceuticals. Receptor Biologix is a pioneer in developing pan-HER ligand traps to treat cancer and other diseases. Both companies are privately owned. The financial conditions of the deal have not been disclosed.

“Receptor BioLogix’s innovative pan-HER ligand trap technology is an excellent fit with our scientific and strategic focus,” says Kirsten Drejer, CEO of Symphogen, in a press statement.

Symphogens objective is to develop novel biologics explicitly designed to adress the complexity of disease. The goal is to achieve better efficacy than single-targeted drugs that fail to account for the complex nature of many diseases.

“We expect our established infrastructure and highly relevant expertise in developing complex biologics will facilitate the rapid progress of the pan-HER cancer program, which we believe has breakthrough potential,” Kirsten Drejer adds.

{{ visitor.ipAccess.member.name }}

{{ visitor.ipAccess.corporateClient.name }}

{{ visitor.person.name }}

Symphogen buys tumor blocking technology

Medlemsnytt

Mest läst

Senaste nytt

Utvalda artiklar

Utvalda nyheter från förstasidan

Novo Nordisk rasar på börsen efter resultat i fetmastudie

Efter haveriet – Region Skåne skjuter upp Millennium-start

Återfinn julefriden – med Life Science Sweden

Delseger i domstol för entreprenör som miste sitt bolag

Bioarctic i miljardavtal med läkemedelsjätte

Andra Nordiska Medier

Nyhetsbrev

Sänd till en kollega